Bharat Parenterals Ltd. · BSE:BPLPHARMA
Bharat Parenterals — Investor Presentation (February 2024)
32 slides from Bharat Parenterals's investor presentation, February 2024
Slide 1: Bharat Parenterals Limited
Bharat Parenterals Limited
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions, which include words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “pl
Slide 3: Table of contents
Table of contents 1 Market overview 4-7 2 Group overview 8 – 27 3 Financial update 28 - 32 3
Slide 4: Market overview
Market overview 4
Slide 5: Global medicine spending to reach $1.9 trillion by 2027
Global medicine spending to reach $ 1.9 trillion by 2027 with a few key themes having the greatest impact on growth and profitability Global medicine market spending1 Key themes in the generic finished dosage formulations space 2,000 1 GEOGRAPHY • High volume growth and negligible price erosion in e
Slide 6: Emerging markets expected to see high growth in spending and volume
Emerging markets expected to experience high growth in spending and volume, while both volume and spending growth to be muted in the developed markets 1 Population driven volumes and shift towards more expensive medicines because of improved healthcare penetration and rising per capital income will
Slide 7: Branded generics and specialty medicines expected to be most rewarding spaces
Branded generics in emerging markets and specialty medicines in developed markets expected to be the most rewarding spaces 2 Specialty medicines will be one of the most rewarding spaces in 3 The branded generics segment will be the most attractive in developed markets as the share of spending on the
Slide 8: Group overview
Group overview 8
Slide 9: The BPL group is built to develop and manufacture FDFs for global markets
The BPL group is built to develop and manufacture FDFs for global markets… Key milestones Group overview Bharat Parenterals Pvt. Ltd. (listed holding company) 7 Manufacturing formulations for emerging markets Incorporation Commenced Listing Established Key therapies: Anti-infectives, anesthesia, pai
Slide 10: Presence spanning the most attractive spaces in the global FDF market
…with a presence spanning the most attractive spaces in the global FDF market… Specialty and complex HIGH Manufacturing of select products Development, developed by generics partnering, Innoxel and BPL manufacturing of for emerging complex dosage markets forms, 505 b(2)s Niche products primarily for
Slide 11: Poised to achieve rapid revenue growth and margin expansion
…Poised to achieve rapid revenue growth and margin expansion over the next few years… 1 Deep entrenchment in high-growth geographies enabled by experience of 3+ decades Bharat Parenterals Solid core business primed for growth and margin expansion Regulatorily approved manufacturing and R&D infrastru
Slide 12: Deep entrenchment in high-growth geographies
1 Deep entrenchment in high-growth geographies enabled by experience of 3+ decades Bharat Parenterals BPL enjoys long-standing presence and commercial relationships in high-growth geographies BPL’s therapy area focus Western Europe Eastern Europe North America 28% 1.6% China 45% 1.2% 23% 0.0% 19% 8.
Slide 13: Regulatorily accredited manufacturing infrastructure
1 Regulatorily accredited manufacturing infrastructure Bharat Parenterals • 3 independent and dedicated production blocks: General, Beta Lactam, and Cephalosporin • Separate service floor for all sections to minimize personnel movement across sections and reduce probability of contamination Key • Se
Slide 14: Product registrations to realign geography focus
1 Product registrations designed to achieve growth and margin expansion by realigning BPL’s geography focus… Bharat Parenterals Product registration pipeline aims to diversify geography mix Diversification to achieve growth and margin expansion First-time filings in new countries to New product fili
Slide 15: Therapy area focus and product mix
1 …Therapy area focus, and product mix Bharat Parenterals Sound strategy guiding therapy area-wise objectives Therapy area Thoughtfully designed product registration pipeline Strategy Current Future • Anti-infectives are competitive spaces with moderate margins • BPL has selectively filed newer clas
Slide 16: Founding team with the perfect blend of skills
2 Founding team with the perfect blend of skills to build a regulated market CDMO success story Bharat Parenterals Pillars of a regulated market CDMO success story Operational excellence Differentiated R&D skill set Wide clinical experience Robust regulatory & compliance Deep commercial networks Mr.
Slide 17: State-of-the-art manufacturing infrastructure
2 Supported by a truly state-of-the-art manufacturing infrastructure Overview Capabilities and capacity Differentiated SKID manufacturing Bharat Parenterals Overview Located in Vadodara with a total Facility has been designed to support scale up manufacturing area of 350,000 sqft and commercial supp
Slide 18: Differentiated technology platforms
2 Identified a set of differentiated technology platforms… Bharat Parenterals Extended release Oral solid to oral liquid Other products with high Particulate injectables Dual chamber bags injectables conversions barriers to entry • Particulate injectables are • Extended release injectables are • Ora
Slide 19: Solutions for unmet healthcare needs
2 …With the ability to formulate solutions for unmet healthcare needs… Category Drug characteristics Impact Bharat Parenterals • The encapsulated drug is protected from rapid degradation and elimination by the body • The drug circulates in the body for longer, allowing for modified drug release prof
Slide 20: Demonstrated track record of commercial success
2 …And demonstrated track record of commercial success Existing commercial products based on these technologies address large markets and have witnessed low competition and price erosion Market landscape Bharat Parenterals Attractive addressable Products Therapy area Active Active 505 (b)(2) No. of
Slide 21: CDMO strengths: particulate injectables
2 Innoxel has strengths across the CDMO continuum to address complexities of the technology platforms Particulate injectables Bharat Parenterals Commercial Development BA/BE studies ANDA/ NDA filing manufacturing • Level of formulation and analytical • Complex BA/BE studies where a • Usually filed t
Slide 22: CDMO strengths: extended release injectables
2 Innoxel has strengths across the CDMO continuum to address complexities of the technology platforms Extended release injectables Bharat Parenterals Commercial Development Clinical work ANDA/ NDA filing manufacturing • Absorption characteristics of the drug at the • 505 (b)(2) filings require exten
Slide 23: CDMO strengths: oral solid to oral liquid conversions
2 Innoxel has strengths across the CDMO continuum to address complexities of the technology platforms Oral solid to oral liquid conversions Bharat Parenterals Development BA/ BE/PK studies ANDA/ NDA filing Commercial manufacturing • Right excipients must be identified • For oral solid to liquid conv
Slide 24: Innoxel's pipeline attuned to the market
2 Innoxel’s pipeline is highly attuned to the market and leverages the team’s experience and expertise in complex injectables… Bharat Parenterals Therapy Tech/ Top 5 therapy areas by 2027 global spending Innoxel's drug Filing route area complexity Oncology 377 13-16% Large part of pipeline composed
Slide 25: Solutions that meet significant unmet healthcare needs
2 …and provides solutions that meet significant unmet healthcare needs Bharat Parenterals Drug Therapeutic area Unmet need Innoxel's solution Tech complexity Filing type Current therapies (oral/transdermal) Modification of currently approved first line INX1011 Alzheimer's must be taken daily, and ha
Slide 26: Innoxel's near term pipeline
2 Innoxel’s near term pipeline Bharat Parenterals Pivotal Filing Approval Innoxel's Therapy Tech/ Formulation Pre-clinical Tech Exhibit Filing route bio/Clinical (expected (expected drug area Complexity development studies transfer batches trials date) date) INX1014 # Confidential Confidential ANDA,
Slide 27: Varenyam Bio leverages Innoxel's portfolio and BPL's market access
3 Varenyam Bio leverages Innoxel’s complex product portfolio & BPL’s market access to further expand the group Bharat Parenterals MARKET ACCESS Leverage BPL’s market access to sell in high-growth markets – EU, Brazil, Colombia, South Africa, Australia, India EU GMP & WHO GMP approved (expected to be
Slide 28: Financial update
Financial update 28
Slide 29: Financial metrics | Consolidated numbers
Financial metrics | Consolidated numbers Total operating revenue (INR crore) EBITDA (INR crore and as %) PAT (INR crore and as %) 6.9% 18.4% 11 16.0% 42 6.4% 3 16 218 23 139 9 FY 2018 FY 2023 Revenue from operations Other operating income FY 2018 FY 2023 FY 2018 FY 2023 Capital expenditure (INR cror
Slide 30: Financial metrics | Standalone numbers
Financial metrics | Standalone numbers Total operating revenue (INR crore) EBITDA (INR crore and as %) PAT (INR crore and as %) 10.7% 11 22.2% 51 24 16.7% 7.1% 3 218 138 24 10 FY 2018 FY 2023 Revenue from operations Other operating income FY 2018 FY 2023 FY 2018 FY 2023 Capital expenditure (INR cror
Slide 31: Consolidated key financials Q3 FY24
Financial metrics | Consolidated key financials Q3 FY 24 Figures in INR crore Particulars Q3 FY 2024 Q3 FY 2023 Change (%) 9M FY 2024 9M FY2023 Change (%) Revenue from operations 59.8 59.0 +1.4% 189.5 167.0 +13.5% Other operating revenue 1.2 1.9 -36.8% 5.0 5.8 -13.8% Total operating revenue 61.0 60.
Slide 32: Standalone key financials Q3 FY24
Financial metrics | Standalone key financials Q3 FY 24 Figures in INR crore Particulars Q3 FY 2024 Q3 FY 2023 Change (%) 9M FY 2024 9M FY2023 Change (%) Revenue from operations 58.8 59.0 -0.4% 188.5 167.0 +12.9% Other operating revenue 1.2 1.9 -36.8% 5.0 5.8 -13.8% Total operating revenue 60.0 60.9
Bharat Parenterals — Investor Presentation (February 2024) on 6ix